BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen K, Liu B, Yu B, Zhong W, Lu Y, Zhang J, Liao J, Liu J, Pu Y, Qiu L, Zhang L, Liu H, Tan W. Advances in the development of aptamer drug conjugates for targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017;9. [PMID: 27800663 DOI: 10.1002/wnan.1438] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhu H, Wu E, Pan Z, Zhang C, Zhang Y, Liao Q, Wang Y, Sun Y, Ye M, Wu W. Development of an Aptamer-Based Molecular Tool for Specifically Targeting Microglia via the CD64 Protein. Anal Chem 2023;95:3238-46. [PMID: 36716100 DOI: 10.1021/acs.analchem.2c04084] [Reference Citation Analysis]
2 Wang H, Su Y, Chen D, Li Q, Shi S, Huang X, Fang M, Yang M. Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases. Front Pharmacol 2023;14:1119431. [PMID: 36825156 DOI: 10.3389/fphar.2023.1119431] [Reference Citation Analysis]
3 Kar A, Rout SR, Giri L, Sahebkar A, Kesharwani P, Dandela R. Aptamer-functionalized nanoparticles for targeted cancer therapy. Aptamers Engineered Nanocarriers for Cancer Therapy 2023. [DOI: 10.1016/b978-0-323-85881-6.00020-8] [Reference Citation Analysis]
4 Guo K, Ma X, Li J, Zhang C, Wu L. Recent advances in combretastatin A-4 codrugs for cancer therapy. Eur J Med Chem 2022;241:114660. [PMID: 35964428 DOI: 10.1016/j.ejmech.2022.114660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang W, Gao Y, Chen Y, Wang W, Li Q, Huang Z, Zhang J, Xiang Q, Wu ZS. Outward Movement of Targeting Ligands from a Built-In Reserve Pool in Nuclease-Resistant 3D Hierarchical DNA Nanocluster for in Vivo High-Precision Cancer Therapy. Adv Sci (Weinh) 2022;:e2203698. [PMID: 36253152 DOI: 10.1002/advs.202203698] [Reference Citation Analysis]
6 Chen Y, Li W, Xing H. Chemistries and applications of DNA-natural product conjugate. Front Chem 2022;10:984916. [DOI: 10.3389/fchem.2022.984916] [Reference Citation Analysis]
7 Gao F, Yin J, Chen Y, Guo C, Hu H, Su J. Recent advances in aptamer-based targeted drug delivery systems for cancer therapy. Front Bioeng Biotechnol 2022;10:972933. [DOI: 10.3389/fbioe.2022.972933] [Reference Citation Analysis]
8 Liu Y, Deng Y, Li S, Wang-ngai Chow F, Liu M, He N. Monitoring and detection of antibiotic residues in animal derived foods: Solutions using aptamers. Trends in Food Science & Technology 2022;125:200-35. [DOI: 10.1016/j.tifs.2022.04.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Parihar A, Singhal A, Kumar N, Khan R, Khan MA, Srivastava AK. Next-Generation Intelligent MXene-Based Electrochemical Aptasensors for Point-of-Care Cancer Diagnostics. Nanomicro Lett 2022;14:100. [PMID: 35403935 DOI: 10.1007/s40820-022-00845-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
10 Liu S, Xu Y, Jiang X, Tan H, Ying B. Translation of aptamers toward clinical diagnosis and commercialization. Biosens Bioelectron 2022;208:114168. [PMID: 35364525 DOI: 10.1016/j.bios.2022.114168] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
11 Zhang N, Wang J, Bing T, Liu X, Shangguan D. Transferrin receptor-mediated internalization and intracellular fate of conjugates of a DNA aptamer. Mol Ther Nucleic Acids 2022;27:1249-59. [PMID: 35282414 DOI: 10.1016/j.omtn.2022.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Xie D, Wang Z, Li J, Guo D, Lu A, Liang C. Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment. Front Oncol 2022;12:843345. [DOI: 10.3389/fonc.2022.843345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Kulabhusan PK, Jeevanandam J, Acquah C, Danquah MK. Aptamer-mediated drug delivery system for cardiovascular diseases. Combination Drug Delivery Approach as an Effective Therapy for Various Diseases 2022. [DOI: 10.1016/b978-0-323-85873-1.00009-5] [Reference Citation Analysis]
14 Krissanaprasit A, Key CM, Pontula S, LaBean TH. Self-Assembling Nucleic Acid Nanostructures Functionalized with Aptamers. Chem Rev 2021;121:13797-868. [PMID: 34157230 DOI: 10.1021/acs.chemrev.0c01332] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
15 Tivon Y, Falcone G, Deiters A. Protein Labeling and Crosslinking by Covalent Aptamers. Angew Chem 2021;133:16035-40. [DOI: 10.1002/ange.202101174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Tivon Y, Falcone G, Deiters A. Protein Labeling and Crosslinking by Covalent Aptamers. Angew Chem Int Ed Engl 2021;60:15899-904. [PMID: 33928724 DOI: 10.1002/anie.202101174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Iturriaga-Goyon E, Buentello-Volante B, Magaña-Guerrero FS, Garfias Y. Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers in Eye Pathological Angiogenesis. Cells 2021;10:1455. [PMID: 34200613 DOI: 10.3390/cells10061455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yan J, Gao T, Lu Z, Yin J, Zhang Y, Pei R. Aptamer-Targeted Photodynamic Platforms for Tumor Therapy. ACS Appl Mater Interfaces 2021;13:27749-73. [PMID: 34110790 DOI: 10.1021/acsami.1c06818] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
19 Huang Z, Wang D, Long CY, Li SH, Wang XQ, Tan W. Regulating the Anticancer Efficacy of Sgc8-Combretastatin A4 Conjugates: A Case of Recognizing the Significance of Linker Chemistry for the Design of Aptamer-Based Targeted Drug Delivery Strategies. J Am Chem Soc 2021;143:8559-64. [PMID: 34097382 DOI: 10.1021/jacs.1c03013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
20 Yoon S, Go G, Yoon Y, Lim J, Lee G, Lee S. Harnessing the Physiological Functions of Cellular Prion Protein in the Kidneys: Applications for Treating Renal Diseases. Biomolecules 2021;11:784. [PMID: 34067472 DOI: 10.3390/biom11060784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Liu R, Zuo R, Hudalla GA. Harnessing molecular recognition for localized drug delivery. Adv Drug Deliv Rev 2021;170:238-60. [PMID: 33484737 DOI: 10.1016/j.addr.2021.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
22 Tan Y, Li Y, Qu YX, Su Y, Peng Y, Zhao Z, Fu T, Wang XQ, Tan W. Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment. ACS Appl Mater Interfaces 2021;13:9436-44. [PMID: 33306339 DOI: 10.1021/acsami.0c18282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
23 Bottari F, Daems E, de Vries A, Van Wielendaele P, Trashin S, Blust R, Sobott F, Madder A, Martins JC, De Wael K. Do Aptamers Always Bind? The Need for a Multifaceted Analytical Approach When Demonstrating Binding Affinity between Aptamer and Low Molecular Weight Compounds. J Am Chem Soc 2020;142:19622-30. [DOI: 10.1021/jacs.0c08691] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
24 Dai R, Wu Z, Chu HY, Lu J, Lyu A, Liu J, Zhang G. Cathepsin K: The Action in and Beyond Bone. Front Cell Dev Biol 2020;8:433. [PMID: 32582709 DOI: 10.3389/fcell.2020.00433] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 24.0] [Reference Citation Analysis]
25 Liu X, Tang I, Wainberg ZA, Meng H. Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation. Small 2020;16:e2000673. [PMID: 32406992 DOI: 10.1002/smll.202000673] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
26 Fu Z, Xiang J. Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy. Int J Mol Sci 2020;21:E2793. [PMID: 32316469 DOI: 10.3390/ijms21082793] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 17.3] [Reference Citation Analysis]
27 Zhong W, Zhang Y, Tan W, Zhang J, Liu J, Wang G, Liao J, Liu B, Chen K, Yu B, Deng Y, Zou Y, Pu Y, Liu H. Adipose specific aptamer adipo-8 recognizes and interacts with APMAP to ameliorates fat deposition in vitro and in vivo. Life Sci 2020;251:117609. [PMID: 32272180 DOI: 10.1016/j.lfs.2020.117609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Alqaraghuli HGJ, Kashanian S, Rafipour R. A Review on Targeting Nanoparticles for Breast Cancer. Curr Pharm Biotechnol 2019;20:1087-107. [PMID: 31364513 DOI: 10.2174/1389201020666190731130001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
29 Wang SY, Hu HZ, Qing XC, Zhang ZC, Shao ZW. Recent advances of drug delivery nanocarriers in osteosarcoma treatment. J Cancer 2020;11:69-82. [PMID: 31892974 DOI: 10.7150/jca.36588] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 18.3] [Reference Citation Analysis]
30 Santini BL, Zúñiga-Bustos M, Vidal-Limon A, Alderete JB, Águila SA, Jiménez VA. In Silico Design of Novel Mutant Anti-MUC1 Aptamers for Targeted Cancer Therapy. J Chem Inf Model 2020;60:786-93. [PMID: 31657548 DOI: 10.1021/acs.jcim.9b00756] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
31 Liang ZM, Peng YH, Chen Y, Long LL, Luo HJ, Chen YJ, Liang YL, Tian YH, Li SJ, Shi YS, Zhang XM. The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease. Nucleic Acid Ther 2019;29:359-66. [PMID: 31513457 DOI: 10.1089/nat.2019.0812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
32 Citartan M, Kaur H, Presela R, Tang TH. Aptamers as the chaperones (Aptachaperones) of drugs-from siRNAs to DNA nanorobots. Int J Pharm 2019;567:118483. [PMID: 31260780 DOI: 10.1016/j.ijpharm.2019.118483] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Zhong W, Pu Y, Tan W, Liu J, Liao J, Liu B, Chen K, Yu B, Hu Y, Deng Y, Zhang J, Liu H. Identification and Application of an Aptamer Targeting Papillary Thyroid Carcinoma Using Tissue-SELEX. Anal Chem 2019;91:8289-97. [PMID: 31141341 DOI: 10.1021/acs.analchem.9b01000] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
34 Bamburowicz-Klimkowska M, Poplawska M, Grudzinski IP. Nanocomposites as biomolecules delivery agents in nanomedicine. J Nanobiotechnology 2019;17:48. [PMID: 30943985 DOI: 10.1186/s12951-019-0479-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
35 Andorfer R, Alper JD. From isolated structures to continuous networks: A categorization of cytoskeleton-based motile engineered biological microstructures. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2019;11:e1553. [PMID: 30740918 DOI: 10.1002/wnan.1553] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Gao G, Liu C, Jain S, Li D, Wang H, Zhao Y, Liu J. Potential use of aptamers for diagnosis and treatment of pancreatic cancer. J Drug Target 2019;27:853-65. [PMID: 30596288 DOI: 10.1080/1061186X.2018.1564924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Kim MW, Jeong HY, Kang SJ, Jeong IH, Choi MJ, You YM, Im CS, Song IH, Lee TS, Lee JS, Lee A, Park YS. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer. Theranostics 2019;9:837-52. [PMID: 30809312 DOI: 10.7150/thno.30228] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 14.0] [Reference Citation Analysis]
38 Liu M, Khan A, Wang Z, Liu Y, Yang G, Deng Y, He N. Aptasensors for pesticide detection. Biosens Bioelectron 2019;130:174-84. [PMID: 30738246 DOI: 10.1016/j.bios.2019.01.006] [Cited by in Crossref: 141] [Cited by in F6Publishing: 149] [Article Influence: 35.3] [Reference Citation Analysis]
39 Parashar A, Pandey KK, Yadav ML. Different Approaches for Aptamer Conjugated Drugs Preparation. Aptamers 2019. [DOI: 10.1007/978-981-13-8836-1_6] [Reference Citation Analysis]
40 Yang Z, He G, Cai D, Ren Z. Photothermal Heating-Induced Localized Structural Disruption in a Poly-ε-caprolactone Nanocarrier System for Controlled Drug Delivery. ACS Appl Bio Mater 2019;2:464-9. [DOI: 10.1021/acsabm.8b00662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
41 Balachandran A, Zambre A, Kainth JS, Nagarajha Selvan LD, Parameswaran S, Afrasiabi Z, Krishnakumar S, Kannan R, Upendran A. Targeting HMGA protein inhibits retinoblastoma cell proliferation. RSC Adv 2018;8:31510-4. [PMID: 35548247 DOI: 10.1039/c8ra06026f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Röthlisberger P, Hollenstein M. Aptamer chemistry. Adv Drug Deliv Rev 2018;134:3-21. [PMID: 29626546 DOI: 10.1016/j.addr.2018.04.007] [Cited by in Crossref: 170] [Cited by in F6Publishing: 138] [Article Influence: 34.0] [Reference Citation Analysis]
43 Bottari F, Blust R, De Wael K. Bio(inspired) strategies for the electro-sensing of β-lactam antibiotics. Current Opinion in Electrochemistry 2018;10:136-42. [DOI: 10.1016/j.coelec.2018.05.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
44 Vandghanooni S, Eskandani M, Barar J, Omidi Y. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective. J Mol Med (Berl) 2018;96:885-902. [PMID: 30056527 DOI: 10.1007/s00109-018-1669-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
45 Zhou W, Zhang Y, Zeng Y, Peng M, Li H, Sun S, Ma B, Wang Y, Ye M, Liu J. Screening and characterization of an Annexin A2 binding aptamer that inhibits the proliferation of myeloma cells. Biochimie 2018;151:150-8. [PMID: 29906496 DOI: 10.1016/j.biochi.2018.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
46 Dean SN, Turner KB, Medintz IL, Walper SA. Targeting and delivery of therapeutic enzymes. Ther Deliv 2017;8:577-95. [PMID: 28633594 DOI: 10.4155/tde-2017-0020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
47 Powell Gray B, Kelly L, Ahrens DP, Barry AP, Kratschmer C, Levy M, Sullenger BA. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 2018;115:4761-6. [PMID: 29666232 DOI: 10.1073/pnas.1717705115] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
48 Dou XQ, Wang H, Zhang J, Wang F, Xu GL, Xu CC, Xu HH, Xiang SS, Fu J, Song HF. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity. Int J Nanomedicine 2018;13:763-76. [PMID: 29440899 DOI: 10.2147/IJN.S149887] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 9.6] [Reference Citation Analysis]
49 Ladju RB, Pascut D, Massi MN, Tiribelli C, Sukowati CHC. Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma. Oncotarget 2018;9:2951-61. [PMID: 29416827 DOI: 10.18632/oncotarget.23359] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
50 Wu H, Wang M, Dai B, Zhang Y, Yang Y, Li Q, Duan M, Zhang X, Wang X, Li A, Zhang L. Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics. Drug Deliv 2017;24:1216-29. [PMID: 28845698 DOI: 10.1080/10717544.2017.1367976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]